拉米夫定与恩替卡韦治疗慢性乙型肝炎的临床疗效比较  

Clinical comparison of antiviral effects of Lamivudine and Entecavir for patients with chronic hepatitis B

作　　者：陈如大[1] 李鹏翀[1] 黄英[2] 陈翔[1] 邓冲[1] 冯智敏[1] 

机构地区：[1]广东省佛山市南海区人民医院药学科,广东佛山528200 [2]广东省佛山科学技术学院药学系,广东佛山528000

出　　处：《中国现代医生》2015年第10期103-105,共3页China Modern Doctor

基　　金：广东省佛山市卫生局医学科研课题(2014238)

摘　　要：目的比较拉米夫定与恩替卡韦治疗慢性乙型肝炎的临床疗效。方法采用回顾性分析方法观察我院慢性乙型肝炎患者60例,其中30例服用拉米夫定,30例服用恩替卡韦,定期复查肝肾功能、HBV DNA及乙肝三系,观察治疗12、24、48周时的ALT复常率、HBV DNA阴转率和不良反应。结果治疗后,拉米夫定组和恩替卡韦组的HBV DNA转阴率和ALT复常率比较,差异无统计学意义(P>0.05),但恩替卡韦组的HBV DNA转阴率和ALT复常率较拉米夫定组高,且自24周始恩替卡韦组的血清HBV DNA表达水平低于拉米夫定组(P<0.05)。两组患者均有持续的应答,且治疗过程中未发生与观察药物相关的严重不良反应。结论恩替卡韦在治疗过程中更能有效抑制慢性乙型肝炎病毒。Objective To compare the antiviral effects of lamivudine and entecavir for patients with chronic hepatitis B. Methods 60 CHB patients were divided into two groupslamivudine group（30 cases）and entecavir group（30 cases）. Liver and kidney function,HBV DNA and HBV serum markers were examined regularly. And ALT normalization,un-detectable HBV DNA and their adverse reactions were observed at 12,24 and 48 weeks. Results There was no signifi-cant difference in ALT normalization,undetectable HBV DNA between lamivudine group and entecavir group although there were higher rates of entecavir group after treatment. However, there was a significant difference in reproduction number of HBV DNA between two groups after 24 weeks,and there were less reproduction numbers of HBV DNA of entecavir group. Two groups of patients had sustained response data. Adverse reactions did not occur during treatment. Conclusion Entecavir is more effective in inhibiting reproduction of HBV than that of lamivudine.

关 键 词：慢性乙型肝炎 拉米夫定 恩替卡韦 

分 类 号：R978.7[医药卫生—药品]